Marshall Wace LLP Acquires 137,354 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Marshall Wace LLP raised its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 16.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 950,948 shares of the medical device company’s stock after acquiring an additional 137,354 shares during the quarter. Marshall Wace LLP owned about 1.45% of Tandem Diabetes Care worth $34,253,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of TNDM. AlphaQuest LLC boosted its position in shares of Tandem Diabetes Care by 138.7% in the 4th quarter. AlphaQuest LLC now owns 931 shares of the medical device company’s stock worth $34,000 after purchasing an additional 541 shares during the last quarter. Jones Financial Companies Lllp grew its position in shares of Tandem Diabetes Care by 195.8% during the 4th quarter. Jones Financial Companies Lllp now owns 1,130 shares of the medical device company’s stock worth $41,000 after buying an additional 748 shares during the period. Assetmark Inc. increased its stake in shares of Tandem Diabetes Care by 77.5% in the 4th quarter. Assetmark Inc. now owns 1,225 shares of the medical device company’s stock valued at $44,000 after acquiring an additional 535 shares during the last quarter. McIlrath & Eck LLC acquired a new stake in shares of Tandem Diabetes Care in the 3rd quarter valued at approximately $52,000. Finally, Smartleaf Asset Management LLC grew its holdings in Tandem Diabetes Care by 163.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company’s stock valued at $65,000 after purchasing an additional 1,101 shares during the period.

Tandem Diabetes Care Stock Down 2.3 %

NASDAQ:TNDM opened at $16.86 on Friday. Tandem Diabetes Care, Inc. has a twelve month low of $15.75 and a twelve month high of $53.69. The firm has a market capitalization of $1.12 billion, a price-to-earnings ratio of -8.74 and a beta of 1.52. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29. The stock’s 50 day moving average price is $21.77 and its two-hundred day moving average price is $30.12.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on TNDM shares. Citigroup cut shares of Tandem Diabetes Care from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $35.00 to $24.00 in a research report on Tuesday, March 4th. The Goldman Sachs Group lowered their price target on Tandem Diabetes Care from $42.00 to $24.00 and set a “neutral” rating for the company in a report on Monday, March 3rd. Canaccord Genuity Group reiterated a “buy” rating and issued a $63.00 price objective on shares of Tandem Diabetes Care in a research report on Wednesday, February 26th. Morgan Stanley downgraded shares of Tandem Diabetes Care from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $45.00 to $22.00 in a report on Wednesday, March 5th. Finally, Robert W. Baird lowered their price objective on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a “neutral” rating for the company in a research report on Thursday, February 27th. Nine research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $43.88.

Insider Activity at Tandem Diabetes Care

In other news, COO Jean-Claude Kyrillos bought 10,538 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was acquired at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the purchase, the chief operating officer now owns 10,538 shares of the company’s stock, valued at approximately $190,948.56. This trade represents a ? increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 2.20% of the stock is owned by company insiders.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.